NCT07133074 Allergy Delabeling in Antibiotic Stewardship - Intervention
| NCT ID | NCT07133074 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Beta Lactam Allergy |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,800 participants |
| Start Date | 2026-04-20 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 3,800 participants in total. It began in 2026-04-20 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Eligibility Criteria
Inclusion Criteria: * all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service * reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem) Exclusion Criteria: * patients with a history of severe cutaneous adverse reaction * patients with a history of Stevens-Johnson syndrome * patients with a history of toxic epidermal necrolysis * patients with a history of drug-induced exfoliative dermatitis * patients with a history of drug reaction with eosinophilia and systemic symptoms * patients with a history of acute generalized exanthematous pustulosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07133074 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Beta Lactam Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07133074 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07133074 currently recruiting?
Yes, NCT07133074 is actively recruiting participants. Contact the research team at ebbing@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07133074 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07133074 clinical trial?
NCT07133074 is sponsored by Abramson Cancer Center at Penn Medicine. The trial plans to enroll 3,800 participants.